Skip to main content
Fig. 4 | Cancer Cell International

Fig. 4

From: LMW-PTP targeting potentiates the effects of drugs used in chronic lymphocytic leukemia therapy

Fig. 4

Morin treatment in combination with conventional drugs impairs CXCR4-dependent adhesion and VLA-4 expression in Mec-1 cells. a Quantification by flow cytometry of the percentage of Mec-1 cells untreated or treated with 0.1 μM ibrutinib or 3.5 μM fludarabine or 50 μM morin or the combination of morin with either fludarabine or ibrutinib for 24 h, that adhered to 48-well plates coated with 10 μg/mL fibronectin following a 10 min ìtreatment with 100 ng/mL CXCL12. The data, which refer to quadruplicate samples from three independent experiments, are presented as fold of adherent cells in CXCL12 stimulated samples versus the corresponding unstimulated controls. b Quantitative RT-PCR analysis of VLA-4 mRNA on Mec-1 cells treated as in panel A. The relative gene transcript abundance was determined on triplicate samples using the ddCt method (n = 3). c Flow cytometric analysis of VLA-4 on Mec-1 cells treated as in panel A and permeabilized (n = 3). Error bars, SD; ***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05

Back to article page